Teleflex Incorporated (NYSE: TFX) develops, manufactures and supplies predominantly single-use medical devices. Its continuing portfolio serves vascular access, interventional and surgical procedures, primarily in hospitals and healthcare settings, through direct sales teams and distributors.
Loading the company summary…
A snapshot of what TELEFLEX INC owns and owes at a point in time.
Read the company’s balance sheet in the original annual reports below.
Browse original filingsSee the original statement for its reporting period, currency, and unit.
3 reports in this collection
| Report period | Filed with SEC | Form | Source |
|---|---|---|---|
| Dec 31, 20230000096943-24-000036 | Feb 23, 2024 | 10-K | Open 10-Ksec.gov |
| Dec 31, 20240000096943-25-000031 | Feb 28, 2025 | 10-K | Open 10-Ksec.gov |
| Dec 31, 20250000096943-26-000019 | Feb 27, 2026 | 10-K | Open 10-Ksec.gov |
Dates describe the filing metadata. Figures and reporting periods should be checked against the original statement. SEC links open in a new tab.
Teleflex is becoming a smaller, more concentrated medical-device company, but its transformation has not yet produced stronger underlying profitability. The 2025 acquisition of BIOTRONIK’s Vascular Intervention business drove much of the subsequent revenue expansion, while integration costs, tariffs and acquisition accounting weighed on margins. Large write-downs in businesses designated for sale produced a substantial 2025 consolidated loss. After the latest annual filing, first-half 2026 continuing cash flow recovered, partly through working-capital improvements and a litigation settlement, even as continuing earnings declined. The OEM sale closed on August 3, 2026, and funded a $700 million loan repayment. Acute Care and Interventional Urology remained pending in the latest supplied operating disclosure. Further benefits depend on integration, remaining disposal execution and removing stranded costs; temporary service income and buyback-supported EPS are not substitutes for durable operating improvement.
Sources: 10-K · 2025-12-31 · 10-Q · 2026-06-30 · 8-K · 2026-08-03 · EX-99.1 · 2026-08-06
Teleflex’s continuing products include Arrow vascular-access devices, EZ-IO intraosseous access, QuikClot hemostats, coronary and peripheral intervention devices, and Weck surgical products. Single-use consumption creates repeat purchasing needs, but not contracted recurring revenue: customers typically order for delivery within days or weeks. Procedure volumes, reimbursement, distributor inventory and competing treatments influence demand. Manufacturing concentration in Mexico, Malaysia, the Czech Republic and the United States creates supply-chain and trade-policy exposure.
The 2025 annual report excludes Acute Care, Interventional Urology and OEM from continuing operations for every comparative year, although their sales were then pending. Its continuing revenue series therefore cannot be spliced into the broader totals originally published for 2023 and 2024. Geographic segments are Americas, EMEA and Asia; global product categories are a different breakdown, not additional revenue.
Sources: 10-K · 2025-12-31 · 10-Q · 2026-06-30 · 10-K · 2024-12-31
In 2025, continuing revenue reached $1,992.713 million, up a reported 17.2%. The acquired Vascular Intervention business contributed $202.4 million, while existing-product volumes, new products and Italian reserve adjustments also helped. Continuing gross margin fell to 56.2% from 61.0%, reflecting acquisition-related amortization, tariffs and other cost pressures. Continuing income was $58.530 million; the $905.640 million consolidated loss principally reflected discontinued-business impairments and disposal valuation charges, not an equivalent cash outflow.
After the annual filing, first-half 2026 revenue increased 30.6% to $1,118.594 million, but continuing income fell to $36.924 million from $120.508 million. Company-defined pro forma adjusted constant-currency growth was 4.9%, using a hypothetical acquisition-adjusted comparison rather than historical Teleflex revenue alone. Adjusted operating margin also fell, to 18.8% from 24.0%, showing that deterioration extended beyond GAAP exclusions. Management subsequently said integration was taking longer than expected.
Sources: 10-K · 2025-12-31 · 10-Q · 2026-06-30 · EX-99.1 · 2026-08-06 · EX-99.2 · 2026-08-06
Continuing operating cash flow fell to $96.682 million in 2025, against $95.236 million of capital expenditure. Acquisition receivables, integration costs and the nonrepeat of pension-surplus inflows weakened conversion. Businesses designated for disposal separately generated $243.995 million of operating cash, making their removal economically significant despite their accounting losses.
First-half 2026 continuing operating cash flow recovered to $138.559 million from a $9.296 million outflow. Inventory released cash, tax-related outflows narrowed and a patent settlement supplied $25 million. These benefits did not represent profit growth. At June 30, continuing cash was $300.159 million, excluding $16.760 million restricted for retirement-plan contributions; gross borrowing principal was $2.825 billion. Neither later disposal proceeds nor the subsequent loan repayment belongs in those quarter-end balances.
Sources: 10-K · 2025-12-31 · 10-Q · 2026-06-30
OEM closed on August 3, 2026 for $1.5 billion cash, subject to adjustments. Detailed pro forma disclosures estimated approximately $1.245 billion after taxes and transaction costs; broader disclosures rounded this to approximately $1.2 billion or $1.25 billion. Teleflex subsequently confirmed repayment of its $700 million term A-2 loan. It also completed $250 million of second-quarter open-market repurchases. A separate $250 million accelerated repurchase agreement was entered August 7, but the supplied record does not confirm its scheduled payment, final shares or settlement.
Sources: 8-K · 2026-08-03 · EX-99.1 · 2026-08-03 · 10-Q · 2026-06-30 · 8-K · 2026-08-07
Acute Care and Interventional Urology remained pending, with fourth-quarter 2026 completion anticipated in the August 6 quarterly filing after extended FTC review. Teleflex retains Palette tax and milestone disputes, while OEM supply and transition arrangements preserve operational dependencies. Expected restructuring savings are conditional, and temporary service benefits do not establish a permanent earnings stream. Tariffs, sterilization capacity, regulatory recertification and competing therapies remain material constraints. The August outlook lowered revenue expectations while increasing adjusted EPS guidance partly through capital allocation, not an improvement in the sales outlook.
Sources: 8-K · 2026-03-11 · 10-Q · 2026-06-30 · EX-99.1 · 2026-08-06 · EX-99.1 · 2026-08-03
USD 1.992713 bn
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 1.992713 bn | 17.2% |
| 2024 | USD 1.699546 bn | -0.8% |
| 2023 | USD 1.712441 bn | — |
GAAP net revenue, excluding discontinued operations; comparative periods recast.
Sources: 10-K · 2025-12-31
USD -905.64 m
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing_and_discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD -905.64 m | — |
GAAP consolidated net income or loss including continuing and discontinued operations.
Sources: 10-K · 2025-12-31
USD 69.675 m
FY2024 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing_and_discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2024 | USD 69.675 m | -80.4% |
| 2023 | USD 356.328 m | — |
GAAP consolidated net income or loss including continuing and discontinued operations.
Sources: 10-K · 2025-12-31
USD 96.682 m
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 96.682 m | -68.0% |
| 2024 | USD 301.882 m | 46.4% |
| 2023 | USD 206.138 m | — |
Net cash provided by operating activities of continuing operations; excludes discontinued operating cash flows.
Sources: 10-K · 2025-12-31
USD 243.995 m
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 243.995 m | -26.9% |
| 2024 | USD 333.856 m | 9.6% |
| 2023 | USD 304.5 m | — |
Net operating cash flow of discontinued businesses, before their investing cash flows.
Sources: 10-K · 2025-12-31
Reading times are estimates for the English text. Financial tables and charts may take additional time.
